We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 1-20 of 10,000 results
  1. Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review

    Background

    Esophageal motility disorders are a group of disorders associated with dysfunctional swallowing resulting from impaired neuromuscular...

    Arman Shafiee, Razman Arabzadeh Bahri, ... Mostafa Gholami in BMC Gastroenterology
    Article Open access 22 May 2023
  2. Effect of phosphodiesterase type 5 inhibitors on surgical outcome of ventricular septal defect and pulmonary hypertension patients

    Background

    Children with ventricular septal defect (VSD) and large systemic-to-pulmonary shunts eventually develop pulmonary hypertension (PH). The...

    Khaled Ahmed Shams, Dalia Monir Ellahony, ... Rania Salah Elzayat in The Egyptian Heart Journal
    Article Open access 21 May 2024
  3. Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s Disease: A retrospective cohort study

    Treatment with Phosphodiesterase Type 5 inhibitors (PDE5is) has shown promise in managing Peyronie’s disease (PD) during its active phase. In a...

    Emil Durukan, Rune Kraglund, ... Mikkel Fode in International Journal of Impotence Research
    Article Open access 16 January 2024
  4. Targeting Aquaporin-5 by Phosphodiesterase 4 Inhibition Offers New Therapeutic Opportunities for Ovarian Ischemia Reperfusion Injury in Rats

    This study aimed to examine the effect of Phosphodiesterase 4 (PDE4) inhibition on Aquaporin-5 (AQP5) and its potential cell signaling pathway in the...

    Ayse Bozkurt, Zeynep Karakoy, ... Elif Cadirci in Reproductive Sciences
    Article Open access 07 March 2024
  5. Phosphodiesterase-5 inhibitors use and the risk of alzheimer's disease: a systematic review and meta-analysis

    Background

    The management of Alzheimer's disease (AD) poses considerable challenges, necessitating the pursuit of innovative therapeutic approaches....

    Moaz Elsayed Abouelmagd, Maickel Abdelmeseh, ... Abdallah Abbas in Neurological Sciences
    Article Open access 25 May 2024
  6. Phosphodiesterase Type 5 Inhibitors and Oral Nitrates in Male Patients with Ischemic Heart Disease

    Purpose of Review

    This review sought to define the mechanism of the drug-drug interaction between phosphodiesterase-type-5 (PDE-5) inhibitors and...

    Matthew J. Morrisette, Steven P. Dunn in Current Cardiology Reports
    Article 19 April 2023
  7. Predictors of the response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension: an analysis of the Spanish registry

    Background

    Achieving and maintaining a low-risk profile is associated with favorable outcome in pulmonary arterial hypertension (PAH). The effects of...

    Agustin R. Garcia, Isabel Blanco, ... Joan A. Barberà in Respiratory Research
    Article Open access 15 September 2023
  8. The spreading information of YouTube videos on Phosphodiesterase 5 inhibitors: a worrisome picture from one of the most consulted internet source

    Several previous studies on YouTube TM information on medical topics have already been published. The current study aimed to evaluate the quality...

    Gabriele Pezone, Claudia Collà Ruvolo, ... Nicola Longo in International Journal of Impotence Research
    Article 21 October 2023
  9. Congenital diaphragmatic hernia: phosphodiesterase-5 and Arginase inhibitors prevent pulmonary vascular hypoplasia in rat lungs

    Background

    Severe pulmonary hypoplasia related to congenital diaphragmatic hernia (CDH) continues to be a potentially fatal condition despite advanced...

    Alberto Toso, Oscar Aránguiz, ... Javier Kattan in Pediatric Research
    Article 23 November 2022
  10. Efficacy of a phosphodiesterase type 5 inhibitor on the pulmonary artery index and postoperative hemodynamics after a Fontan operation

    There have been no reports regarding the influence of a change in the pulmonary artery index before or after a Fontan operation. Moreover, the...

    Takuro Kojima, Koichi Toda, ... Naokata Sumitomo in Heart and Vessels
    Article 18 May 2022
  11. Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety

    The coexistence of cardiovascular disease and erectile dysfunction is widespread, possibly owing to underlying endothelial dysfunction in both...

    Sumon Roy, Robert A. Kloner, ... Ion S. Jovin in Cardiovascular Drugs and Therapy
    Article 15 October 2021
  12. Contemporary cost-analysis comparison of direct-to-consumer vs. traditional prescriptions of phosphodiesterase-5 inhibitors

    After a focused telehealth visit, patients can now access phosphodiesterase-5 inhibitor (PDE5 inhibitor) prescriptions through online...

    Douglas Schneider, Charles A. Loeb, ... Faysal A. Yafi in International Journal of Impotence Research
    Article 09 April 2022
  13. Phosphodiesterase type 5 inhibitors use and risk of colorectal cancer: a systematic review and meta-analysis

    Background

    Experimental evidence has revealed that phosphodiesterase five inhibitors (PDE5is) increase epithelial barrier function and suppress...

    Akshaya Srikanth Bhagavathula, Wubshet Tesfaye, Kota Vidyasagar in International Journal of Colorectal Disease
    Article 10 September 2021
  14. Reno-protective effects of Phosphodiesterase 5 inhibitors

    The kidneys are vital organs that play an important role in removing waste materials from the blood, electrolyte balance, blood pressure regulation,...

    Enis Rauf Coskuner, Burak Ozkan in Clinical and Experimental Nephrology
    Article 22 March 2021
  15. The effect of Sildenafil, a phosphodiesterase-5 inhibitor, on tendon healing: an experimental study in rat model of achilles tendon injury

    Introduction

    Sildenafil Citrate has various effects on the body, including widening blood vessels, inhibiting platelet aggregation, promoting the...

    Vahap Kurt, Savaş Guner, ... Omer Eronat in Archives of Orthopaedic and Trauma Surgery
    Article 26 December 2023
  16. Short-term outcomes of phosphodiesterase type 5 inhibitors for fetal growth restriction: a study protocol for a systematic review with individual participant data meta-analysis, aggregate meta-analysis, and trial sequential analysis

    Abstract Background

    Early onset fetal growth restriction secondary to placental insufficiency can lead to severe maternal and neonatal morbidity and...

    Jessica Liauw, Katie Groom, ... Peter von Dadelszen in Systematic Reviews
    Article Open access 03 December 2021
  17. Beyond traditional pharmacology: evaluating phosphodiesterase inhibitors in autism spectrum disorder

    Fernando E. Padovan-Neto, Ana Júlia de Oliveira Cerveira, ... Danilo Leandro Ribeiro in Neuropsychopharmacology
    Article 11 April 2024
Did you find what you were looking for? Share feedback.